# US 2021/0275576 A1 · Molecular hydrogen-containing composition for prevention and/or improvement of genetic disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275576 A1
- Document ID: US20210275576A1
- Status: Published application
- Kind: A1
- Application number: 17/189,973
- Filed: 2021-03-02
- Published: 2021-09-09
- Earliest claimed: 2020-03-06
- Assignees: Miz Co., Ltd.
- Applicants: MiZ Company Limited
- Inventors: Fumitake SATOH; Bunpei SATO; Yusuke ICHIKAWA; Shinichi HIRANO; Ryosuke KUROKAWA
- Web page: https://patentgrep.com/patent/US20210275576A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition for prevention and/or improvement of a genetic disorder. More specifically, the present invention provides a composition for prevention and/or improvement of a genetic disorder and a symptom associated with the genetic disorder in a subject, comprising molecular hydrogen as an active ingredient.

## Claims

### Claim 1

A method for preventing and/or improving a genetic disorder and a symptom associated with the genetic disorder in a subject, comprising administering a composition containing an effective amount of molecular hydrogen.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the genetic disorder is a disease associated with chromosomal aberration and/or mitochondrial DNA abnormalities.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the genetic disorder is a disease selected from the group consisting of Down syndrome, Wilson disease, Edwards syndrome, Patau syndrome, Turner syndrome, Klinefelter syndrome, Apert syndrome, Crouzon syndrome, 22q11.2 deletion syndrome, Williams syndrome, Laurence-Moon-Biedl syndrome, Prader-Willi syndrome, Angelman syndrome, Kallmann syndrome, Aicardi-Goutieres syndrome, Miller-Dieker syndrome, Rubinstein-Taybi syndrome, Cornelia de Lange syndrome, cri-du-chat syndrome, super female, super male, and mitochondrial disease.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the symptom associated with the genetic disorder is one or more symptoms selected from the group consisting of physical development delay, intellectual disabilities, memory disturbance, mental retardation, thyroid disorder, early menopause, premature aging, physical deformities, organ deformities, heart disease, depression, leukemia, strabismus, thyroid abnormalities, and loss of QOL associated with these symptoms.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition is a liquid composition or a gas composition comprising the molecular hydrogen.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the liquid composition has a hydrogen concentration of 1 to 10 ppm.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the gas composition has a hydrogen concentration of higher than zero (0) and not higher than 18.5% by volume.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the subject is a mammalian subject.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the subject is a human.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the composition is produced by using a hydrogen gas generating apparatus, a hydrogen water generating apparatus, or a hydrogen gas adding apparatus.
